« Back to Record
Citation APA

Lonardi, S., André, T., Wong, K. Y. M., Morse, M. M., McDermott, R., Hill, A., Hendlisz, A., Lenz, H.-J., Leach, J., Moss, R. R., Cao, A. Z., Ledeine, J. M., Kopetz, S., & Overman, M. J. (2017). Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 28, vi3. doi:10.1093/annonc/mdx422.001


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/301708

Lonardi, S., André, T., Wong, K. Y. M., Morse, M. M., McDermott, R., Hill, A., Hendlisz, A., Lenz, H.-J., Leach, J., Moss, R. R., Cao, A. Z., Ledeine, J. M., Kopetz, S., & Overman, M. J. (2017). Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 28, vi3. doi:10.1093/annonc/mdx422.001